Comparative Pharmacology
Head-to-head clinical analysis: MEPERIDINE HYDROCHLORIDE PRESERVATIVE FREE versus METHADOSE.
Head-to-head clinical analysis: MEPERIDINE HYDROCHLORIDE PRESERVATIVE FREE versus METHADOSE.
MEPERIDINE HYDROCHLORIDE PRESERVATIVE FREE vs METHADOSE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Meperidine is a synthetic opioid agonist that exerts its analgesic effects by binding to mu-opioid receptors in the central nervous system, thereby mimicking the actions of endogenous opioids. It also has some kappa-opioid receptor activity and weak serotonergic effects.
Methadone is a mu-opioid receptor agonist; it also acts as an NMDA receptor antagonist and inhibits serotonin and norepinephrine reuptake, contributing to its analgesic and detoxification effects. It has a long half-life and reduces opioid craving and withdrawal symptoms.
50-100 mg IM/SC every 3-4 hours as needed; 25-50 mg IV slowly every 3-4 hours as needed.
Oral: 20-40 mg once daily, titrated to effect; for opioid dependence, typical maintenance 80-120 mg/day. IV: 2.5-10 mg every 8-12 hours.
None Documented
None Documented
Terminal elimination half-life: 2.5–4 hours (mean 3.2 h). In cirrhosis, half-life prolonged to 7–11 hours; in elderly, half-life extends up to 8 hours. Normeperidine (active metabolite) half-life: 15–30 hours (accumulates with renal impairment).
Terminal elimination half-life range: 8–59 hours (mean ~20–35 hours). In chronic use, half-life may increase due to accumulation. Context: The long half-life supports once-daily dosing for opioid dependence but requires careful titration to avoid accumulation.
Primarily renal (90% as metabolites, ~5-30% unchanged); biliary/fecal excretion accounts for <10%. Urinary excretion is pH-dependent; acidic urine increases elimination.
Primarily renal (approximately 80%) as inactive metabolites, with about 20% eliminated via feces. Less than 10% excreted unchanged.
Category D/X
Category C
Opioid Agonist
Opioid Agonist